Nice:
Diwan believes this drug could be more effective than any of the experimental Ebola drugs currently being sent to the region. And unlike those drugs, Diwan’s drug is not expected to have adverse side effects. Plus, his company has the capability at its Shelton facility to produce it in great enough numbers to handle an outbreak. More importantly, because the nanoviiricide is “broad-spectrum” drug, it is expected to work against all versions of Ebola, unlike the other experimental drugs.
The only problem is the concept for the Ebola nanoviricides can’t be tested readily. Diwan’s company conducts all animal and live-disease testing offsite. With Ebola this becomes complicated. There are only a handful of labs in the world with active strains of the virus, and these labs are currently overwhelmed because of the outbreak.
When Ebola is brought under control, or possibly if it continues to spiral out of control and the world gets desperate, Diwan’s drug will be tested. NanoViricides has connected with the US Army Medical Research Institute for Infectious Diseases (USAMRIID) as well as the National Institutes of Health facility (both in Maryland), and they are working out a plan for Ebola drug testing. If the drug is successful, manufacturing could begin in Connecticut.
Market Data 
Markets 
AI
